Opthea to present at upcoming events to highlight work on wet AMD
November 21st 2024Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks.
Read More
FDA authorizes marketing of Valeda Light Delivery System for treatment of patients with dry AMD
November 12th 2024"The De Novo authorization established Valeda as the first device for treatment of dry AMD patients with vision loss and creates a threshold for this novel class of photobiomodulation (PBM) devices..."
Read More
Rensselaer Polytechnic Institute researchers receive grant to study potential dry AMD treatment
November 8th 2024A $6.4 million grant over 5 years from the National Institutes of Health’s National Eye Institute was awarded conduct drug development work and investigational new drug (IND)-enabling toxicology studies.
Read More